Where is Teva Pharmaceutical Industries Limited (TEVA) Headed?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy healthcare stocks to invest in. Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced on February 20 that the U.S. Food and Drug Administration accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension for the treatment of schizophrenia in adults. TEV-‘749 is specialized to improve real-world treatment adherence and help patients maintain long-term stability, and aims to address a critical treatment gap for people living with schizophrenia.

Management reported that there is currently no long-acting olanzapine formulation without an FDA-required Risk Evaluation and Mitigation Strategy, which mandates administration in a certified healthcare facility and requires a 3-hour post-injection monitoring period. It further stated that TEV-‘749, administered as a once-monthly subcutaneous injection in the Phase 3 SOLARIS trial, exhibited an efficacy and safety profile consistent with currently available olanzapine formulations and did not show any evidence for the need for post-injection monitoring.

In another development, Teva Pharmaceutical Industries Limited (NYSE:TEVA) and Sanofi announced on February 17 positive results from the RELIEVE UCCD long-term extension study of duvakitug, exhibiting durable clinical and endoscopic efficacy maintained over 44 weeks in patients with ulcerative colitis and Crohn’s disease that initially responded to the induction phase. Duvakitug is an investigational human monoclonal antibody targeting TL1A, and RELIEVE UCCD LTE is a double-blind randomized study looking into the long-term efficacy, safety, and tolerability of duvakitug in UC and CD, which are the two most common forms of inflammatory bowel disease.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, produces, and sells medicines. Its operations are divided into the US, Europe, and International Markets geographical segments. Each business segment covers the entire product portfolio in that region, including specialty, generics, and over-the-counter (OTC) products.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.